Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.Division of Urology, University of Sao Paulo, Sao Paulo, Brazil.
Oncologic outcomes in men with radiation-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP) are poorly defined.
To identify predictors of biochemical recurrence (BCR), metastasis, and death following SRP to help select patients who may benefit from SRP.
This is a retrospective, international, multi-institutional cohort analysis. There was a median follow-up of 4.4 yr following SRP performed on 404 men with radiation-recurrent PCa from 1985 to 2009 in tertiary centers.
Intervention: Open SRP.
BCR after SRP was defined as a serum prostate-specific antigen (PSA) ≥0.1 or ≥0.2ng/ml (depending on the institution). Secondary end points included progression to metastasis and cancer-specific death.
Median age at SRP was 65 yr of age, and median pre-SRP PSA was 4.5ng/ml. Following SRP, 195 patients experienced BCR, 64 developed metastases, and 40 died from PCa. At 10 yr after SRP, BCR-free survival, metastasis-free survival, and cancer-specific survival (CSS) probabilities were 37% (95% confidence interval [CI], 31-43), 77% (95% CI, 71-82), and 83% (95% CI, 76-88), respectively. On preoperative multivariable analysis, pre-SRP PSA and Gleason score at postradiation prostate biopsy predicted BCR (p=0.022; global p< 0.001) and metastasis (p=0.022; global p< 0.001). On postoperative multivariable analysis, pre-SRP PSA and pathologic Gleason score at SRP predicted BCR (p=0.014; global p< 0.001) and metastasis (p< 0.001; global p< 0.001). Lymph node involvement (LNI) also predicted metastasis (p=0.017). The main limitations of this study are its retrospective design and the follow-up period.
In a select group of patients who underwent SRP for radiation-recurrent PCa, freedom from clinical metastasis was observed in >75% of patients 10 yr after surgery. Patients with lower pre-SRP PSA levels and lower postradiation prostate biopsy Gleason score have the highest probability of cure from SRP.
Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'oglio M, Srougi M, Scardino PT, Eastham JA. Are you the author?
Reference: Eur Urol. 2011 Mar 17. Epub ahead of print.